Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LIXT
#3737
Lixte Biotechnology Holdings, Inc. Common Stock
2.9
0
-2.68%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-2.68%
Monthly Change
-15.20%
6 month change
-15.20%
Year Change
+110.14%
Previous Close
2.9
8
Open
2.8
9
Bid
Ask
Low
2.8
5
High
2.9
4
Volume
20
Markets
US Stock Market
Healthcare
LIXT
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.35 M
1.37 M
1.67 M
2.25 M
2.68 M
—
Valuation ratios
Enterprise value
—
—
—
4.45 M
7.91 M
45.66 M
Price to earnings ratio
—
—
—
-0.86
-1.28
-7.08
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
-1.02
-1.44
-9.3
Price to book ratio
—
—
—
8.87
-1.71
-5.68
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.62
-1.32
-1.14
-1.18
-3.13
-2.02
Return on equity %
0.65
-1.4
-1.22
-1.27
-4.33
-2.95
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
24.15
16.81
14.08
13.73
3.6
17.65
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2.92
-2.24
-1.41
-0.93
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
3.38
2.19
0.46
1.77
Net current asset value per share
—
—
3.51
2.25
0.51
2.58
Tangible book value per share
—
—
1.05
0.26
-1.19
-1.26
Working capital per share
—
—
3.26
2.09
0.37
1.95
Book value per share
—
—
1.05
0.26
-1.19
-1.26
News
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary
LIXTE expands clinical trial for ovarian cancer treatment
Lixte Biotechnology stock falls after $4.3 million direct offering
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering
Lixte Biotechnology stock falls after $4.3 million direct offering
Lixte Biotechnology raises $4.3 million in registered direct offering
Lixte Biotechnology shareholders approve board nominees and stock plan amendment
Lixte Biotechnology stock falls after acquiring UK-based Liora
LIXTE Biotechnology acquires UK-based proton therapy developer Liora
Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants
BOCA RATON - Lixte Biotechnology refreshes leadership and diversifies assets
LIXTE Biotechnology announces leadership changes and $5 million funding